Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Stetler-Stevenson M et al. Cytometry B Clin Cytom. 2015 Apr 23. doi: 10.1002/cyto.b.21249. [Epub ahead of print].
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Cejalvo MJ et al. Future Oncol. 2015 Apr 10:1-16. [Epub ahead of print].
Lenalidomide in multiple myeloma.
Kim Y et al. Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407. Epub 2015 Apr 5.
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point.
Dimopoulos MA et al. Haematologica. 2015 Apr 3. pii: haematol.2014.120790. [Epub ahead of print]
Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma.
Reyskens M et al. Osteoporos Int. 2015 Apr 24. [Epub ahead of print].
Improved survival of older patients with multiple myeloma in the era of novel agents.
Mey UJ et al. Hematol Oncol. 2015 Apr 21. doi: 10.1002/hon.2205. [Epub ahead of print].
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Mohty M et al. Bone Marrow Transplant. 2015 Apr 20. doi: 10.1038/bmt.2015.83. [Epub ahead of print].
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM et al. Eur J Haematol. 2015 Apr 18. doi: 10.1111/ejh.12571. [Epub ahead of print].
Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.
Matuschek C et al. Radiat Oncol. 2015 Mar 28;10(1):71. doi: 10.1186/s13014-015-0374-z.
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study.
Musto P et al. Stem Cell Res Ther. 2015 Apr 17;6(1):64. [Epub ahead of print].
Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).
Osborne TR et al. BMC Cancer. 2015 Apr 14;15:280. doi: 10.1186/s12885-015-1261-6.
Multiple myeloma or metastatic carcinoma breast — Diagnostic dilemma in a case presenting with lytic bony lesion.
Chandra H et al. Breast Dis. 2015 Apr 16. [Epub ahead of print].
Bortezomib-Containing Regimens Are Effective in Multiple Myeloma – Results of a Non-Interventional Phase IV Study.
Knauf W et al. Oncol Res Treat. 2015;38(4):167-73. doi: 10.1159/000381297. Epub 2015 Mar 31.
Leishmaniasis involving the bone marrow of a patient with multiple myeloma.
Alahmadi M et al. Ann Hematol. 2015 Apr 17. [Epub ahead of print].
Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
Graff TM et al. Bone Marrow Transplant. 2015 Apr 13. doi: 10.1038/bmt.2015.46. [Epub ahead of print].
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Festuccia M et al. Expert Opin Biol Ther. 2015 Apr 12:1-16. [Epub ahead of print].
Current therapeutic strategies for multiple myeloma.
Torimoto Y et al. Int J Clin Oncol. 2015 Apr 9. [Epub ahead of print].
Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains.
Lakdawalla D et al. Health Aff (Millwood). 2015 Apr 1;34(4):555-61. doi: 10.1377/hlthaff.2014.0639.
Introduction to a series of reviews on multiple myeloma.
San Miguel JF et al. Blood. 2015 Apr 2. pii: blood-2015-01-613596. [Epub ahead of print].
New criteria for response assessment: role of minimal residual disease in multiple myeloma.
Paiva B et al. Blood. 2015 Apr 2. pii: blood-2014-11-568907. [Epub ahead of print].
Frontline therapy of multiple myeloma.
Moreau P et al. Blood. 2015 Apr 2. pii: blood-2014-09-568915. [Epub ahead of print].
Smoldering multiple myeloma.
Rajkumar SV et al. Blood. 2015 Apr 2. pii: blood-2014-09-568899. [Epub ahead of print].
Pathogenesis beyond the cancer clone(s) in multiple myeloma.
Bianchi G et al. Blood. 2015 Apr 2. pii: blood-2014-11-568881. [Epub ahead of print].
Treatment options for relapsed and refractory multiple myeloma.
Nooka AK et al. Blood. 2015 Apr 2. pii: blood-2014-11-568923. [Epub ahead of print].
Panobinostat: first global approval.
Garnock-Jones KP. Drugs. 2015 Apr;75(6):695-704. doi: 10.1007/s40265-015-0388-8.
Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time.
Hieke S et al. Clin Cancer Res. 2015 Apr 1;21(7):1530-6. doi: 10.1158/1078-0432.CCR-14-2154.
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR et al. Curr Med Res Opin. 2015 Apr 17:1-11. [Epub ahead of print].
Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis.
Kharroubi SA et al. Med Decis Making. 2015 Apr;35(3):351-60. doi: 10.1177/0272989X15575285.
The relative length of the patient and the primary care interval in patients with 28 common and rarer cancers.
Lyratzopoulos G et al. Br J Cancer. 2015 Mar 31;112 Suppl:S35-40. doi: 10.1038/bjc.2015.40.